CN114874237A - Refining method of cefotaxime sodium - Google Patents
Refining method of cefotaxime sodium Download PDFInfo
- Publication number
- CN114874237A CN114874237A CN202210421360.3A CN202210421360A CN114874237A CN 114874237 A CN114874237 A CN 114874237A CN 202210421360 A CN202210421360 A CN 202210421360A CN 114874237 A CN114874237 A CN 114874237A
- Authority
- CN
- China
- Prior art keywords
- cefotaxime
- refining
- temperature
- turbulent flow
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 title claims abstract description 29
- 229960002727 cefotaxime sodium Drugs 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 23
- 238000007670 refining Methods 0.000 title claims abstract description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000013078 crystal Substances 0.000 claims abstract description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 20
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims abstract description 20
- 238000003756 stirring Methods 0.000 claims abstract description 20
- 238000001914 filtration Methods 0.000 claims abstract description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 11
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 11
- 235000017281 sodium acetate Nutrition 0.000 claims abstract description 11
- 239000001632 sodium acetate Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000005406 washing Methods 0.000 claims abstract description 7
- 239000012046 mixed solvent Substances 0.000 claims abstract description 5
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 3
- 239000000706 filtrate Substances 0.000 claims abstract description 3
- 238000001035 drying Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 abstract description 15
- 239000000047 product Substances 0.000 abstract description 15
- 238000002425 crystallisation Methods 0.000 abstract description 6
- 239000002904 solvent Substances 0.000 abstract description 5
- 238000001291 vacuum drying Methods 0.000 abstract description 5
- 230000008025 crystallization Effects 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- -1 oxime cephalosporins Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 1
- AAEQXEDPVFIFDK-UHFFFAOYSA-N 3-(4-fluorobenzoyl)-2-(2-methylpropanoyl)-n,3-diphenyloxirane-2-carboxamide Chemical compound C=1C=CC=CC=1NC(=O)C1(C(=O)C(C)C)OC1(C=1C=CC=CC=1)C(=O)C1=CC=C(F)C=C1 AAEQXEDPVFIFDK-UHFFFAOYSA-N 0.000 description 1
- OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 description 1
- 206010005940 Bone and joint infections Diseases 0.000 description 1
- 206010051548 Burn infection Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
- C07D501/34—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/12—Separation; Purification
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
Abstract
The invention discloses a refining method of cefotaxime sodium, which comprises the following steps: (1) dissolving cefotaxime acid into a mixed solvent of water, methanol and acetone, adding sodium acetate, stirring, dissolving and clarifying; (2) adding active carbon, stirring, and filtering; (3) ethyl acetate was added rapidly to the filtrate under intense turbulence; the strong turbulence has Reynolds number more than 11000; (4) growing the crystal under the condition of moderating turbulent flow; the reynolds number of the mild turbulent flow reaches 4000-6000; (5) slowly adding ethyl acetate under a rapid turbulent flow, and continuously growing the crystals, wherein the Reynolds number of the rapid turbulent flow reaches 6500-8000; (6) and after the crystal growth is finished, filtering, washing and vacuum drying to obtain the cefotaxime sodium. The invention adopts rapid turbulent crystallization and various solvents, can increase the solubility of different impurities, reduce the impurity carried by the crystallization and improve the product quality.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a method for refining cefotaxime sodium.
Background
Cefotaxime sodium is the third generation cephalosporin. Semi-synthetic oxime cephalosporins are powerful against gram-negative bacteria, especially against enterobacteria. Is mainly used for respiratory system infection, urinary system infection, biliary tract and intestinal tract infection, skin and soft tissue infection, burn, bone and joint infection and the like caused by sensitive bacteria. The chemical name of cefotaxime acid is: 3-acetoxymethyl-7- [2- (2-amino-4-thiazolyl) -2-methoxyimino ] -acetamido-3-ceph-4-carboxylic acid, the structural formula is as follows:
in the process of storing cefotaxime sodium, the problems of great changes of color grade, impurities and the like easily occur, and the quality of the product is influenced. The crystallization method of cefotaxime sodium usually adopts an anhydrous system crystallization method. For example, CN102584854A discloses a method for preparing cefotaxime sodium crystal in an aqueous solution-free system, which uses formamide, acetamide, dimethyl sulfoxide or methanol as a solvent system. The method is simple and convenient to operate, the production period is short, but the prepared product has high organic solvent residue, high solvent recycling difficulty and poor clarity of a product solution. CN101486719A discloses a crystallization method using acetone aqueous solution as solvent system, which solves the problem of poor clarity of the prepared product solution, but the stability of the product prepared by the method is poor. Therefore, the research on the high-quality cefotaxime sodium product with good clarity, less impurities and good stability is of great significance.
Disclosure of Invention
The invention aims to provide a refining method of cefotaxime sodium, which aims to solve the problems of high impurity content, poor clarity and non-ideal stability of the existing product.
The purpose of the invention is realized as follows: a refining method of cefotaxime sodium comprises the following steps:
(1) dissolving cefotaxime acid into a mixed solvent of water, methanol and acetone, adding sodium acetate, stirring, dissolving and clarifying;
(2) controlling the temperature, adding active carbon, stirring and then filtering;
(3) controlling the temperature, and quickly adding ethyl acetate into the filtrate under strong turbulence; continuously keeping the strong turbulence for 10-60 s, wherein the Reynolds number of the strong turbulence is more than 11000;
(4) controlling the temperature, and growing the crystal under the condition of moderating turbulent flow; the reynolds number of the mild turbulent flow reaches 4000-6000;
(5) controlling the temperature, slowly adding ethyl acetate under a rapid turbulent flow, and continuously growing the crystals, wherein the Reynolds number of the rapid turbulent flow reaches 6500-8000;
(6) and after the crystal growth is finished, filtering, washing and drying to obtain the cefotaxime sodium.
In the step (1), the ratio of the water consumption in the mixed solvent to the feeding amount of cefotaxime acid is 0.1-0.2L: 1 kg; the ratio of the methanol dosage to the feeding amount of cefotaxime acid is 2-3L: 1 kg; the proportion of the acetone dosage to the cefotaxime acid feeding amount is 0.5-1L: 1 kg.
In the step (1), the mass ratio of the added sodium acetate to the cefotaxime acid is 35-45: 200 of a carrier; adding sodium acetate, stirring and dissolving, and controlling the temperature at 0-5 ℃.
In the step (2), the temperature is controlled to be-3-10 ℃.
And (5) controlling the temperature to be 0-5 ℃.
In the step (3), the rapid addition is carried out within 1-10 s.
In the step (3), the feeding amount ratio of the added ethyl acetate to the cefotaxime acid is 2-5L: 1 kg.
In the step (5), the slow addition is carried out at an ethyl acetate flow rate of 20-40 mL/min.
In the step (5), the ratio of the added ethyl acetate to the added cefotaxime acid is 10-14L: 1 kg.
In the step (4) and the step (5), the time for growing the crystal is 20-40 min.
Due to the adoption of the technical scheme, the invention has the technical progress that:
the invention adopts rapid turbulent crystallization, and improves the product quality of cefotaxime sodium.
The invention adopts various solvents during refining, can increase the solubility of different impurities and reduce the impurities carried by the crystals, thereby improving the product quality.
Detailed Description
The invention is further illustrated by the following examples, which are given by way of illustration only and are not intended to limit the scope of the invention in any way.
Procedures and methods not described in detail in the following examples are conventional methods well known in the art, and the reagents used in the examples are either analytically or chemically pure and are either commercially available or prepared by methods well known to those of ordinary skill in the art. The following examples all achieve the objects of the present invention.
Example 1
Adding 25ml of purified water, 580ml of methanol and 200ml of acetone into 200g of cefotaxime acid, and stirring until the mixture is clear; then adding 40g of sodium acetate, controlling the temperature to be 2 +/-2 ℃, stirring, dissolving and clarifying. Then activated carbon was added and stirred, followed by filtration.
Adding 600ml of ethyl acetate in 10s under the turbulent flow state with the Reynolds number of 12000, controlling the temperature to be 2 +/-2 ℃, stirring for 30s, reducing the Reynolds number to 4000, growing the crystals for 30min, and controlling the temperature to be 2 +/-2 ℃.
Adding 2500ml ethyl acetate again for 90min under the condition of the Reynolds number of 6500 turbulent flow, growing the crystal for 30min, and controlling the temperature to be 2 +/-2 ℃. And finally, filtering, washing and vacuum drying to obtain a cefotaxime sodium finished product.
Example 2
Adding 20ml of purified water, 400ml of methanol and 150ml of acetone into 200g of cefotaxime acid, and stirring until the mixture is clear; then adding 40g of sodium acetate, controlling the temperature to be 2 +/-2 ℃, stirring, dissolving and clarifying. Then activated carbon was added and stirred, followed by filtration.
Adding 1000ml of ethyl acetate in 10s under the turbulent flow state with the Reynolds number of 11000, controlling the temperature to be 2 +/-2 ℃, stirring for 30s, reducing the Reynolds number to 5000, growing the crystals for 20min, and controlling the temperature to be 2 +/-2 ℃.
Adding 2000ml ethyl acetate again in 90min under the condition of reynolds number 7000 turbulence, growing crystal for 20min, controlling the temperature to 2 +/-2 ℃. And finally, filtering, washing and vacuum drying to obtain a cefotaxime sodium finished product.
Example 3
Adding 200g of cefotaxime acid into 40ml of purified water, 600ml of methanol and 100ml of acetone, and stirring until the mixture is clear; then adding 40g of sodium acetate, controlling the temperature to be 2 +/-2 ℃, stirring, dissolving and clarifying. Then activated carbon was added and stirred, followed by filtration.
Under the turbulent flow state with the Reynolds number of 13000, 400ml of ethyl acetate is added within 10s, the temperature is controlled to be 2 +/-2 ℃, the stirring is carried out for 30s, the Reynolds number is reduced to 6000, the crystal growth is carried out for 40min, and the temperature is controlled to be 2 +/-2 ℃.
Adding 2800ml ethyl acetate again in 90min under the condition of 8000 Reynolds number turbulence, growing crystal for 40min, and controlling the temperature to 2 + -2 deg.C. And finally, filtering, washing and vacuum drying to obtain a cefotaxime sodium finished product.
Comparative example 1
Adding 25ml of purified water, 580ml of methanol and 200ml of acetone into 200g of cefotaxime acid, and stirring until the mixture is clear; then adding 40g of sodium acetate, controlling the temperature to be 2 +/-2 ℃, stirring, dissolving and clarifying. Then activated carbon was added and stirred, followed by filtration.
Adding 600ml of ethyl acetate in 10s under the turbulent flow state with the Reynolds number of 12000, controlling the temperature to be 2 +/-2 ℃, stirring for 30s, reducing the Reynolds number to 4000, growing the crystals for 30min, and controlling the temperature to be 2 +/-2 ℃. Adding 2500ml ethyl acetate again in 90min under the condition of maintaining Reynolds number at 4000, growing crystal for 30min, and controlling temperature at 2 + -2 deg.C. And finally, filtering, washing and vacuum drying to obtain a cefotaxime sodium finished product.
The above products were subjected to quality tests, and the results are shown in table 1.
Table 1:
| examples | Example 1 | Example 2 | Example 3 | Comparative example 1 |
| Color grade | Number 1 | Number 1 | Number 1 | Number 2 |
| Content% | 100.5％ | 100.3％ | 100.4％ | 99.4％ |
| Impurity A | 0.35％ | 0.38％ | 0.35％ | 0.45％ |
| Impurity B | 0.24％ | 0.25％ | 0.26％ | 0.36％ |
| Impurity C | / | / | / | / |
| Impurity D | 0.05％ | 0.03％ | 0.04％ | 0.08％ |
| Impurity E | 0.01％ | 0.01％ | 0.01％ | 0.03％ |
| Impurity F | 0.02％ | 0.02％ | 0.03％ | 0.06％ |
| Impurity G | 0.04％ | 0.06％ | 0.05％ | 0.06％ |
| Impurity H | 0.01％ | 0.01％ | 0.01％ | 0.03％ |
| Impurity I | / | / | / | / |
| Impurity J | 0.01％ | 0.01％ | 0.01％ | 0.02％ |
| Impurity K | 0.01％ | 0.01％ | 0.01％ | 0.02％ |
And (3) accelerated test comparison:
the test conditions are as follows: temperature: 40 ℃. + -. 2 ℃, relative humidity: 75% ± 5%, acceleration time: 6 months. The test results are shown in Table 2.
Table 2:
Claims (10)
1. a refining method of cefotaxime sodium is characterized by comprising the following steps:
(1) dissolving cefotaxime acid into a mixed solvent of water, methanol and acetone, adding sodium acetate, stirring, dissolving and clarifying;
(2) controlling the temperature, adding active carbon, stirring and then filtering;
(3) controlling the temperature, and quickly adding ethyl acetate into the filtrate under strong turbulence; continuously keeping the strong turbulence for 10-60 s, wherein the Reynolds number of the strong turbulence is more than 11000;
(4) controlling the temperature, and growing the crystal under the condition of moderating turbulent flow; the reynolds number of the mild turbulent flow reaches 4000-6000;
(5) controlling the temperature, slowly adding ethyl acetate under a rapid turbulent flow, and continuously growing the crystals, wherein the Reynolds number of the rapid turbulent flow reaches 6500-8000;
(6) and after the crystal growth is finished, filtering, washing and drying to obtain the cefotaxime sodium.
2. The method for refining cefotaxime sodium according to claim 1, wherein in the step (1), the ratio of the water consumption in the mixed solvent to the feeding amount of cefotaxime acid is 0.1-0.2L: 1 kg; the ratio of the methanol dosage to the feeding amount of cefotaxime acid is 2-3L: 1 kg; the proportion of the acetone dosage to the cefotaxime acid feeding amount is 0.5-1L: 1 kg.
3. The method for refining cefotaxime sodium according to claim 1, wherein in step (1), the mass ratio of the added sodium acetate to the cefotaxime acid is 35-45: 200 of a carrier; adding sodium acetate, stirring and dissolving, and controlling the temperature at 0-5 ℃.
4. The method for refining cefotaxime sodium according to claim 1, wherein in step (2), the temperature is controlled to be-3-10 ℃.
5. The method for refining cefotaxime sodium according to claim 1, wherein the temperature in the steps (3) to (5) is controlled to be 0-5 ℃.
6. The method for refining cefotaxime sodium according to claim 1, wherein in step (3), the rapid addition is within 1-10 s.
7. The method for refining cefotaxime sodium according to claim 1, wherein in the step (3), the ratio of the charged ethyl acetate to the charged cefotaxime acid is 2-5L: 1 kg.
8. The method for refining cefotaxime sodium according to claim 1, wherein in step (5), the slow addition is performed at an ethyl acetate flow rate of 20-40 mL/min.
9. The method for refining cefotaxime sodium according to claim 1, wherein in the step (5), the ratio of the charged ethyl acetate to the charged cefotaxime acid is 10-14L: 1 kg.
10. The method for refining cefotaxime sodium according to claim 1, wherein the crystal growth time in step (4) and step (5) is 20-40 min.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210421360.3A CN114874237B (en) | 2022-04-21 | 2022-04-21 | Refining method of cefotaxime sodium |
| PCT/CN2023/088936 WO2023202567A1 (en) | 2022-04-21 | 2023-04-18 | Method for refining cefotaxime sodium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210421360.3A CN114874237B (en) | 2022-04-21 | 2022-04-21 | Refining method of cefotaxime sodium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114874237A true CN114874237A (en) | 2022-08-09 |
| CN114874237B CN114874237B (en) | 2024-01-19 |
Family
ID=82670708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210421360.3A Active CN114874237B (en) | 2022-04-21 | 2022-04-21 | Refining method of cefotaxime sodium |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114874237B (en) |
| WO (1) | WO2023202567A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023202567A1 (en) * | 2022-04-21 | 2023-10-26 | 华北制药河北华民药业有限责任公司 | Method for refining cefotaxime sodium |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101486719A (en) * | 2009-02-17 | 2009-07-22 | 福建省福抗药业股份有限公司 | Method for converting cefotaxime acid into sodium salt crystal |
| CN104086569A (en) * | 2014-07-29 | 2014-10-08 | 石药集团中诺药业（石家庄）有限公司 | Preparation method of cefotaxime sodium |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113024580B (en) * | 2021-03-10 | 2022-02-25 | 苏州东瑞制药有限公司 | Preparation method of cefotaxime sodium |
| CN114874237B (en) * | 2022-04-21 | 2024-01-19 | 华北制药河北华民药业有限责任公司 | Refining method of cefotaxime sodium |
-
2022
- 2022-04-21 CN CN202210421360.3A patent/CN114874237B/en active Active
-
2023
- 2023-04-18 WO PCT/CN2023/088936 patent/WO2023202567A1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101486719A (en) * | 2009-02-17 | 2009-07-22 | 福建省福抗药业股份有限公司 | Method for converting cefotaxime acid into sodium salt crystal |
| CN104086569A (en) * | 2014-07-29 | 2014-10-08 | 石药集团中诺药业（石家庄）有限公司 | Preparation method of cefotaxime sodium |
Non-Patent Citations (1)
| Title |
|---|
| 胡文滨: "头孢噻肟钠的精制", 《河北化工》, vol. 34, no. 7, pages 6 - 8 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023202567A1 (en) * | 2022-04-21 | 2023-10-26 | 华北制药河北华民药业有限责任公司 | Method for refining cefotaxime sodium |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023202567A1 (en) | 2023-10-26 |
| CN114874237B (en) | 2024-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114874237B (en) | Refining method of cefotaxime sodium | |
| CN103275150B (en) | A kind of refining and preparation method of erythromycin thiocyanate | |
| CN112661720B (en) | Crystallization process of cefixime side chain acid | |
| CN108948048B (en) | Refining method of cefathiamidine | |
| CN112535666B (en) | Preparation method of high-stability cefuroxime sodium powder injection preparation for injection | |
| CN111548357B (en) | High-purity cefazolin sodium and preparation method of pharmaceutical preparation thereof | |
| CN109824697A (en) | A kind of preparation method of ceftezole acid | |
| CN109232610B (en) | Refining method of cefonicid dibenzylethylenediamine salt | |
| CN108440569B (en) | Preparation method of ceftriaxone sodium spherical crystal | |
| CN109293680B (en) | Preparation method of cefoperazone acid | |
| CN114349768B (en) | Preparation method of cefotaxime acid | |
| CN106565749B (en) | The method for promoting Cefamandole Nafate quality using three-dimensional column plate purification solvent | |
| CN113699209B (en) | 7-ADCA recovery method | |
| CN107793432B (en) | Refining method of ceftriaxone sodium crude salt | |
| CN110974832B (en) | Preparation method of cefamandole nafate for injection | |
| CN110857308B (en) | Preparation method of ceftazidime for injection | |
| CN112358489A (en) | Production method of industrial penicillin sulfoxide product | |
| CN109912625B (en) | Process method for reducing ceftazidime impurity H | |
| CN111793076B (en) | Preparation method of cefpirome sulfate for injection | |
| CN112442048B (en) | Preparation method of cefpiramide sodium | |
| CN112745337B (en) | Preparation method of cefuroxime acid | |
| CN111777625B (en) | Preparation method of ceftizoxime sodium for injection | |
| CN114853786B (en) | Preparation method of cefoxitin sodium powder | |
| CN108299468B (en) | Refining method of cefprozil | |
| CN117860651A (en) | Cefotaxime sodium preparation for injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |